Surmodics (SRDX)
(Delayed Data from NSDQ)
$39.12 USD
-0.22 (-0.56%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $39.14 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Company Summary
Eden Prairie, MN-headquartered Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry. It reports via two segments – Medical Devices and IVD.
The Medical Devices segment ($105.8 million in FY23, 79.8% of FY23 net sales, up 46.1% from FY22) includes the manufacture of performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and structural ...
Company Summary
Eden Prairie, MN-headquartered Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry. It reports via two segments – Medical Devices and IVD.
The Medical Devices segment ($105.8 million in FY23, 79.8% of FY23 net sales, up 46.1% from FY22) includes the manufacture of performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and structural heart, among others. The segment also includes the manufacture of vascular intervention medical devices, including drug-coated balloons (DCBs), mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.
The IVD segment ($26.8 million, 20.2%, down 2.8%) includes the manufacture of chemical and biological components used in IVD immunoassay and molecular tests within the diagnostic and biomedical research markets. The component products include protein stabilizers, substrates, surface coatings and antigens.
Surmodics derives revenues from three primary sources — Product Sales, Royalties & License Fees and R&D.
Product Sales include IVD chemical and biological components, performance coating reagents and vascular intervention medical devices and related products. Royalties & License Fees include performance coating royalties from licensing of its proprietary performance coating technologies to medical device manufacturers (Medical Device segment) and SurVeil DCB license fees associated with exclusive worldwide commercialization rights pursuant to its Development and Distribution Agreement with Abbott Vascular, Inc. (Medical Device segment). The R&D source includes commercial development feasibility services and contract coating services (Medical Device segment) and commercial development services (IVD segment).
General Information
Surmodics, Inc
9924 WEST 74TH STREET
EDEN PRAIRIE, MN 55344
Phone: 952-500-7000
Fax: 952-500-7001
Email: ir@surmodics.com
Industry | Medical - Products |
Sector | Medical |
Fiscal Year End | September |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.27 |
Current Year EPS Consensus Estimate | -0.47 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 39.34 |
52 Week High | 42.44 |
52 Week Low | 25.17 |
Beta | 1.20 |
20 Day Moving Average | 289,800.91 |
Target Price Consensus | 43.00 |
4 Week | -0.58 |
12 Week | -6.11 |
YTD | 8.23 |
4 Week | -2.35 |
12 Week | -10.11 |
YTD | -9.73 |
Shares Outstanding (millions) | 14.27 |
Market Capitalization (millions) | 561.26 |
Short Ratio | NA |
Last Split Date | 12/7/2000 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | 119.21 |
PEG Ratio | NA |
vs. Previous Year | -151.92% |
vs. Previous Quarter | -485.71% |
vs. Previous Year | -42.19% |
vs. Previous Quarter | -5.06% |
Price/Book | 4.75 |
Price/Cash Flow | 50.17 |
Price / Sales | 4.65 |
6/30/24 | 3.88 |
3/31/24 | 13.30 |
12/31/23 | 8.06 |
6/30/24 | 2.59 |
3/31/24 | 8.63 |
12/31/23 | 5.11 |
6/30/24 | 3.98 |
3/31/24 | 4.39 |
12/31/23 | 4.84 |
6/30/24 | 3.22 |
3/31/24 | 3.59 |
12/31/23 | 3.97 |
6/30/24 | 3.89 |
3/31/24 | 11.13 |
12/31/23 | 6.66 |
6/30/24 | -1.16 |
3/31/24 | 9.44 |
12/31/23 | 3.99 |
6/30/24 | -7.58 |
3/31/24 | 12.10 |
12/31/23 | 7.07 |
6/30/24 | 8.28 |
3/31/24 | 8.69 |
12/31/23 | 8.58 |
6/30/24 | 2.09 |
3/31/24 | 2.01 |
12/31/23 | 1.98 |
6/30/24 | 0.25 |
3/31/24 | 0.24 |
12/31/23 | 0.24 |
6/30/24 | 19.99 |
3/31/24 | 19.21 |
12/31/23 | 19.42 |